Plain-English translation of NCT07493135 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new injection called IMV102 for patients with multiple myeloma that has returned or stopped responding to standard treatments. The study will evaluate whether this medication is safe and whether it helps shrink or control the cancer. Researchers will monitor your blood work and tumor response over two years to understand how well the treatment works.
Multiple myeloma is a blood cancer that can become resistant to standard therapies, leaving patients with limited options. This trial exists to see if this new medication offers hope for people whose cancer no longer responds to conventional treatments.
You likely qualify if…
You likely don't qualify if…
You will receive an infusion of IMV102 at the study center. Your blood and urine will be tested before and after the infusion to check how your body responds and for any side effects. You will return for follow-up visits at Day 28, Month 2, Month 3, and then every three months through Month 24 to have imaging scans and blood work to measure how the cancer is responding. The entire study commitment spans approximately two years, unless your disease progresses or you need to start a different treatment sooner.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China